March 2024
1. BURKI T
   Pivotal tuberculosis vaccine trial begins.
   Lancet. 2024;403:1125.
   

   >> Share

   
   
2. BHARGAVA A, Bhargava M, Pai M
   Tuberculosis: a biosocial problem that requires biosocial solutions.
   Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
   

   >> Share

   
   
3. SUBBARAMAN R, Fielding K
   Putting technology to the test in tuberculosis care.
   Lancet. 2024;403:878-879.
   

   >> Share

   
   January 2024
4. WEI X, Hicks JP, Zhang Z, Haldane V, et al
   Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.
   Lancet. 2024 Jan 31:S0140-6736(23)02270-5. doi: 10.1016/S0140-6736(23)02270.
   

   >> Share

   
   November 2023
5. SAMARASEKERA U
   Anurag and Madhavi Bhargava: enhancing TB prevention and care.
   Lancet. 2023;402:1740.
   

   >> Share

   
   October 2023
6. BURKI T
   J&J patent decision to enable generic tuberculosis treatment.
   Lancet. 2023;402:1313.
   

   >> Share

   
   September 2023
7. THE LANCET
   Tuberculosis: a different way of doing things.
   Lancet. 2023;402:937.
   

   >> Share

   
   
8. REID M, Agbassi YJP, Arinaminpathy N, Bercasio A, et al
   Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
   Lancet. 2023 Sep 13:S0140-6736(23)01379-X. doi: 10.1016/S0140-6736(23)01379.
   

   >> Share

   
   
9. BEKO B, Furin J
   Beyond individual inclusion, investment in affected communities is needed to end tuberculosis.
   Lancet. 2023 Sep 13:S0140-6736(23)01892-5. doi: 10.1016/S0140-6736(23)01892.
   

   >> Share

   
   August 2023
10. BHARGAVA A, Bhargava M, Meher A, Benedetti A, et al
    Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.
    Lancet. 2023 Aug 8:S0140-6736(23)01231-X. doi: 10.1016/S0140-6736(23)01231.
    

    >> Share

    
    
11. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.
    

    >> Share

    
    April 2023
12. REID M, Yamey G, Goosby E, Jamison D, et al
    Seizing opportunities to end TB: a call for ambition and optimism on World TB Day.
    Lancet. 2023;401:1153.
    

    >> Share

    
    March 2023
13. KIRBY T
    Ruvandhi Nathavitharana: advancing TB diagnostics and advocacy.
    Lancet. 2023;401:990.
    

    >> Share

    
    
14. KASAEVA T, Dias HM, Pai M
    Fast-tracking progress to End TB: high-level opportunities for investment and action.
    Lancet. 2023;401:975-978.
    

    >> Share

    
    
15. WATTS G
    Bern-Thomas Nyang'wa: getting things done in TB and HIV.
    Lancet. 2023 Mar 17:S0140-6736(23)00576-7. doi: 10.1016/S0140-6736(23)00576.
    

    >> Share

    
    November 2022
16. GOODALL RL, Meredith SK, Nunn AJ, Bayissa A, et al
    Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02078.
    

    >> Share

    
    
17. DHEDA K, Lange C
    A revolution in the management of multidrug-resistant tuberculosis.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02161.
    

    >> Share

    
    
18. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    

    >> Share

    
    
19. JACKSON S, Kabir Z, Comiskey C
    Divergence in pace of decline in tuberculosis rates among migrants versus non-migrants in Ireland from 2011 to 2020.
    Lancet. 2022;400 Suppl 1:S52.
    

    >> Share

    
    October 2022
20. MOK J, Lee M, Kim DK, Kim JS, et al
    9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial i
    Lancet. 2022;400:1522-1530.
    

    >> Share

    
    
21. REUTER A, Furin J
    Celebrating choice in the care of people living with drug-resistant tuberculosis.
    Lancet. 2022;400:1489-1491.
    

    >> Share

    
    August 2022
22. MARKS GB, Horsburgh CR Jr, Fox GJ, Nguyen TA, et al
    Epidemiological approach to ending tuberculosis in high-burden countries.
    Lancet. 2022 Aug 4. pii: S0140-6736(22)01433.
    

    >> Share

    
    March 2022
23. DHEDA K, Pinto L, Mutsvangwa J, Leung CC, et al
    Accelerate investment and action to find the missing patients with tuberculosis.
    Lancet. 2022 Mar 22. pii: S0140-6736(22)00535.
    

    >> Share

    
    
24. WATTS G
    Alberto Garcia-Basteiro: seeking better TB control in Mozambique.
    Lancet. 2022;399:1109.
    

    >> Share

    
    February 2022
25. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    

    >> Share

    
    January 2022
26. VIGNESHWARAN J, Kumar MS, Raghavan V, Sundari S, et al
    Seizures and sideroblastic anaemia in a patient with multidrug-resistant tuberculosis.
    Lancet. 2022;399:393.
    

    >> Share

    
    
27. MCCALL C
    Disrupted care in Papua New Guinea: the harms of COVID-19.
    Lancet. 2022;399:226-227.
    

    >> Share

    
    December 2021
28. HOSSEINPOOR AR, Bergen N, Kirkby K, Schlotheuber A, et al
    Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)02756.
    

    >> Share

    
    November 2021
29. LANE R
    Pascale Ondoa: strengthening laboratory medicine in Africa.
    Lancet. 2021;398:1955.
    

    >> Share

    
    June 2021
30. DESHPANDE AA, Sharma V, Bansal R, Jagia P, et al
    Tension pericardial abscess in a patient with tuberculosis: a rare cause of cardiac tamponade.
    Lancet. 2021;397:e15.
    

    >> Share

    
    May 2021
31. MAKONI M
    Africa's need for more COVID-19 clinical trials.
    Lancet. 2021;397:2037.
    

    >> Share

    
    April 2021
32. WALTER KS, Martinez L, Arakaki-Sanchez D, Sequera VG, et al
    The escalating tuberculosis crisis in central and South American prisons.
    Lancet. 2021 Apr 8. pii: S0140-6736(20)32578.
    

    >> Share

    
    March 2021
33. NKEREUWEM E, Kampmann B, Togun T
    The need to prioritise childhood tuberculosis case detection.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00672.
    

    >> Share

    
    
34. LANE R
    Nicole Salazar-Austin: emerging tuberculosis-HIV research leader.
    Lancet. 2021 Mar 18. pii: S0140-6736(21)00587.
    

    >> Share

    
    January 2021
35. MACLEAN E, Bigio J, Singh U, Klinton JS, et al
    Global tuberculosis awards must do better with equity, diversity, and inclusion.
    Lancet. 2021;397:192-193.
    

    >> Share

    
    September 2020
36. BURKI T
    Inappropriate behaviour claims at Stop TB prompt review.
    Lancet. 2020;396:876.
    

    >> Share

    
    April 2020
37. SUNDEWALL J, Forsberg BC
    Understanding health spending for SDG 3.
    Lancet. 2020 Apr 23. pii: S0140-6736(20)30963.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share